# Medinotec Q1 Net Income Plummets 88% on Margin Pressures

- URL: https://stocks.freetheai.org/news/medinotec-q1-net-income-plummets-88-on-margin-pressures-5a4766
- Published: 2026-10-08T15:31:01Z
- Category: earnings; sentiment: bearish; impact: low
- Symbols: [OTC:MDNC](https://stocks.freetheai.org/symbols/OTC-MDNC)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Medinotec Inc. (OTC:MDNC) reported flat quarterly revenue of $3.2 million for the three months ended August 31, 2026, while its net income plummeted 88% to $40,866. Diluted earnings per share dropped to $0.00, down from $0.03 in the same quarter of the prior year. The sharp decline in profitability was primarily driven by margin compression and inventory-related charges.

The company's gross margin fell to approximately 49% year-to-date, impacted by pricing pressures from its South African distribution network and write-downs on inventory. Medinotec remains highly reliant on a single South African distributor, DISA Life Sciences, which generates between 86% and 88% of its total revenue, limiting near-term diversification.

Investors should monitor the company's expansion in the United States, where year-to-date sales grew 71% to $480,000, led by products like the Trachealator and the newly launched Outflo. However, the U.S. division is still operating at a loss. Future performance will also depend on the commercial progress of its pipeline products, including Cape Cross, Micro CTO, and StaXstop, alongside ongoing regulatory approval efforts in Europe.

## Key points

- Medinotec reported revenue of $3.2 million for the three months ended August 31, 2026, down 1% year-over-year.
- Net income fell 88% to $40,866 due to inventory write-downs and South African distribution pricing.
- The company remains heavily dependent on South African distributor DISA Life Sciences for 86% to 88% of its revenue.
- U.S. sales rose 71% year-to-date to $480,000, though the American business segment remains unprofitable.

## Questions and answers

### Why did Medinotec's net income drop in the quarter ended August 31, 2026?

Net income fell 88% to $40,866 due to margin pressure, inventory write-downs, and pricing challenges in its South African distribution channel.

### How much of Medinotec's revenue comes from South Africa?

Medinotec is highly dependent on South African distribution, with DISA Life Sciences accounting for approximately 86% to 88% of its revenue.

### Is Medinotec growing its sales in the United States?

Yes, U.S. sales rose about 71% year-to-date to $480,000, driven by the Trachealator and the launch of Outflo, though the U.S. segment is still unprofitable.